Currently, there are few data on Antiphospholipid antibodies (aPL Ab) in COVID-19 and it is
unclear if they represent an epiphenomenon or are involved in pathogenesis of COVID-19 …

Background Critically ill patients with coronavirus disease 2019 (COVID-19) have a
profound hypercoagulable state and often develop coagulopathy which leads to organ …

This paper reviewed recent publications in order to assess the likelihood that
antiphospholipid antibody (aPL) contributes to thromboses in COVID-19 patients. 23 studies …

Background Critically ill patients with coronavirus disease 2019 (COVID-19) have a
profound hypercoagulable state and often develop coagulopathy which leads to organ …

Background High incidence of thrombosis in COVID‐19 patients indicates a
hypercoagulable state. Hence, exploring the involvement of antiphospholipid antibodies …

Dear Editor, An unusually high prevalence of thromboembolic events has been observed
during the course of coronavirus disease 2019 (COVID-19), an infection caused by severe …

COVID-19 has led to more than 5 million deaths to date. 1 COVID-19 presentation can range
from a simple asymptomatic viral infection to acute respiratory distress syndrome (ARDS) 2; …

Abstract Objectives Antiphospholipid antibodies (APAs) increase the risk of excessive blood
clotting, but their role in COVID‐19 remains unclear. We aimed to investigate the presence …

Purpose of Review COVID-19 patients have a procoagulant state with a high prevalence of
thrombotic events. The hypothesis of an involvement of antiphospholipid antibodies (aPL) …

Background The significance of antiphospholipid antibodies (aPL) in COVID-19 remains
uncertain. Objectives We determined whether aPL are associated with COVID-19 and/or …